

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,211 B1  
APPLICATION NO. : 09/744289  
DATED : February 22, 2005  
INVENTOR(S) : Szu et al.

Page 1 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title page, under References Cited, OTHER PUBLICATIONS:

Col. 2 Lines 1-27

“Bitzan Me t al, Infection...” should read --Bitzan, M. et al., Infection....--.

“Konadu EY et al., Nov. 1994, Infection and Immunity, Vool. 62(11)...” should read --Konadu EY et al., Nov. 1994, Infection and Immunity, vol. 62(11)....--.

“Harari, I et al., Infection adn Immunity...” should read --Harari, I et al., Infection and Immunity....--.

“...*Escherichia coli* of serotypes O157:h7 and O26:H11...” should read  
---...*Escherichia coli* of serotypes O157:H7 and O26:H11....--.

“Konadu et al., Jun. 26, 1997, Seide presentation...” should read  
--Konadu et al., Jun. 26, 1997, Slide presentation....--.

“Chu, C; Preparation, Characterization, an Immunogencity...” should read  
--Preparation, Characterization, and Immunogenicity....--.

“Gupta, R.K., “Comparitive Immunogencity of Conjugates Composed of  
*Escherichia coli* 0111 O-Specific...” should read --Comparative Immunogenicity of  
Conjugates Composed of *Escherichia coli* O111 O-Specific..... --.

“Konadu et al., “Investigational Vaccine for *Escherichia coli* 0157: Phase 1  
Study of 0157...” should read --Investigational Vaccine for *Escherichia coli* 0157:  
Phase 1 Study of 0157....--.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,211 B1  
APPLICATION NO. : 09/744289  
DATED : February 22, 2005  
INVENTOR(S) : Szu et al.

Page 2 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

“Konadu et al., “Preparation, Characterization and Immunological Properties in Mice of *Escherichia coli* 0157 O-Specific...” should read --Preparation, Characterization and Immunological Properties in Mice of *Escherichia coli* O157 O-Specific...--.

“Taylor et al., Synthesis, Characterization, and Clinical Evaluation of Conjugate Vaccines Composed of the O-Specific...” should read --Taylor et al., Synthesis, Characterization, and Clinical Evaluation of Conjugate Vaccines Composed of the O-Specific...--.

“Human Testing of *E. coli* 0157:H7...” should read --Human Testing of *E. coli* O157:H7...--.

“...Anti-LPS IgG (Preliminary Slide).” should read --...Anti-LPS IgG (Preliminary Slide))--.

“Scheerson, et al., “Quantitative and Qualitative Analyses...” should read --Schneerson, et al., “Quantitative and Qualitative Analyses..”--.

On the Title page Item [57] , in the last sentence of the first paragraph in the Abstract:

“The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against *E. coli*, in particular...” should read --The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against *E. coli*, in particular...--.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,211 B1  
APPLICATION NO. : 09/744289  
DATED : February 22, 2005  
INVENTOR(S) : Szu et al.

Page 3 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

Column 1, lines 12, 22, 25, 26, 29, 32 and 65, "O517" should read --O157--.

Column 1, line 13, "...methods of using of these conjugates and/or compositions..." should read --...methods of using these conjugates and/or compositions....--.

Column 2, lines 5, 17, 18, 20, 21, 22, 26, 32, 35, 38 and 49, "O517" should read --O157--.

Column 2, line 41, "*E. coli*" should read --*E. coli*--.

Column 3, line 7, "( $\geq$  100kD)" should read --( $\leq$  100kD)--.

Column 3, line 15, "B cell" should read --B-cell--.

Column 3, lines 27, 30, 45, 46, 52, 54, 57 and 63, "O517" should read --O157--.

Column 3, lines 54-55, "There also remains a need compositions..." should read --There also remains a need for compositions....--.

Column 3, line 64, "...and compositions thereof, and to methods of using of these..." should read --...and compositions thereof, and to methods of using these....--.

Column 4, lines 7, 11, 13, 22, 27, 32, 41, 64, 65 and 67, "O517" should read --O157--.

Column 4, lines 9-10, "...bacteriostatic activity against against *E. coli*..." should read --...bacteriostatic activity against *E. coli*....--.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,211 B1  
APPLICATION NO. : 09/744289  
DATED : February 22, 2005  
INVENTOR(S) : Szu et al.

Page 4 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 5, lines 9, 11, 13, 14, 15, 18, 19, 22, 26, 30, 31, 37, 38, 42, 47, 51, 56, 58, 60, and 65 should read --O157--.

Column 6, lines 9, 12, 15, 17, 18, 22, and 23, "O517" should read --O157--.

Column 6, line 17, "Additionally, it is may be used..." should read  
---Additionally, it may be used...--.

Column 7, lines 54 and 63, "O517" should read --O157--.

Column 8, lines 11, 25, 47, 55, and 58, "O517" should read --O157--.

Column 9, lines 13, 32, 43, 56, and 61, "O517" should read --O157--.

Column 10, lines 3, 22, 25, and 52, "O517" should read --O157--.

Column 10, line 48 "booster infections..." should read --booster injections...--.

Column 10, line 59 "Geometric mean antibody level (ELISA units)" should read  
--Geometric mean antibody level (ELISA units)--.

Column 12, lines 1, 45, and 46, "O517" should read --O157--.

Column 12, line 4 "...the FDA (BB-IND:5528) and the..." should read ---the  
FDA (BB-IND-5528) and the...--.

Column 13, lines 14, 18, and 67, "O517" should read --O157--.

Column 13, line 28, "...with either of the two DeA-LPS-rFPA conjugates..."  
should read ---with either of the two DeA-LPS-rEPA conjugates...--.

Column 14, Table 3A, line 40, "32.8 (23.51)" should read --32.8 (23-51)--.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,211 B1  
APPLICATION NO. : 09/744289  
DATED : February 22, 2005  
INVENTOR(S) : Szu et al.

Page 5 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 15, Table 4, line 50, ">1.3 x 10<sup>4</sup>" should read -->1.3 x 10<sup>3</sup>--.

Column 16, Table 5, line 4, "...*Escherichia coli* 0157 O-specific..." should read  
--...*Escherichia coli* O157 O-specific...--.

Column 16, lines 18, 21, and 28, "O517" should read --O157--.

Column 16, line 23, "*Shigella* toxin 1 (StxB1)..." should read --*Shigella* toxin I  
(StxB1)...--.

Column 17, lines 12, 14, 46, 48, 57, and 62, "O517" should read --O157--.

Column 18, lines 5, 6, 10, 12, 17, 21, 43, 51, 52, and 64, "O517" should read  
--O157--.

Column 18, line 59, "...point to LPD..." should read --...point to LPS...--.

Column 19, lines 1 and 6, "O517" should read --O157--.

Column 19, line 34, "6. Riley. L. W.," should read --6. Riley, L. W.,"--.

Column 19, lines 41-42, "177 383-387" should read --177, 383-387--.

Column 19, line 56, "91991)." should read --(1991).--.

Column 20, line 4, "*Immun.* 59 4555-4561(1991)." should read --*Immun.* 59,  
4555-4561(1991).--.

Column 20, line 6, "*J. Exp. Med.* 166 1510-1524(1987)." should read --*J. Exp.*  
*Med.* 166, 1510-1524 (1987).--.

Column 20, line 9, "Bockemühl, J., *Int.*" should read --Bockemühl, J., *Int.*--.

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,858,211 B1  
APPLICATION NO. : 09/744289  
DATED : February 22, 2005  
INVENTOR(S) : Szu et al.

Page 6 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 20, line 15, "Gentry M., Dalrymple J.M.," should read -- Gentry M.,  
Dalrymple J.M.,--.


Column 20, line 28, "*J. Clin Microbial.*," should read --*J. Clin. Microbiol.*,--.

Column 20, line 31, "*Lance*" should read --*Lancet*--.

Column 20, line 36, "*Infect. Di.s J.*," should read --*Infect. Dis. J.*,--.

Signed and Sealed this

Sixth Day of March, 2007

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a distinct "D" at the end.

JON W. DUDAS  
*Director of the United States Patent and Trademark Office*